December 1, 2015 | Following a string of Chinese investments into Israeli companies, Hefei Tianhui Incubator of Technologies (HTIT) has invested $50 million in Israeli biomedical company Oramed in exchange for exclusive rights to market Oramed’s oral insulin capsule, ORMD-0801, in China, Hong Kong and Macau. HTIT is partially owned by Sinopharm Group, the largest pharmaceutical company in China, which currently has the largest population of people living with diabetes. Founded in 2006 and led by CEO Nadav Kidron, Oramed has developed a method for oral delivery of drugs which currently are only administered via injection. The company is traded on the Nasdaq with a current market cap of $89.90M
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Can Predict Future Heart Attacks By Analyzing CT Scans
October 01, 2023

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023
Facebook comments